Trials / Completed
CompletedNCT02294942
Extended-Release RANCAD in the Patients With Stable Angina Pectoris
A Double-blind, Randomized, Placebo-controlled, Parallel Study to Evaluate the Effects of add-on RANCAD on Exercise Tolerance and Angina Frequency in Patients With Stable Angina Pectoris.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 75 (actual)
- Sponsor
- TSH Biopharm Corporation Limited · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
A double-blind, randomized, placebo-controlled, parallel study to evaluate the effects of add-on RANCAD on exercise tolerance and angina frequency in patients with stable angina pectoris.
Detailed description
Primary objective is to to determine the effects of add-on RANCAD on exercise treadmill test (ETT) duration at trough plasma level of RANCAD level after 12-weeks therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RANCAD | Extended-Release RANCAD |
Timeline
- Start date
- 2014-10-01
- Primary completion
- 2016-12-01
- Completion
- 2016-12-01
- First posted
- 2014-11-19
- Last updated
- 2017-04-28
Locations
6 sites across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT02294942. Inclusion in this directory is not an endorsement.